EPIGENESIS PHARMACEUTICALS

Serial Number 78790767
606

Registration Progress

Application Filed
Jan 12, 2006
Under Examination
Dec 12, 2006
Approved for Publication
Aug 30, 2006
Published for Opposition
Sep 19, 2006
Registered

Trademark Image

EPIGENESIS PHARMACEUTICALS

Basic Information

Serial Number
78790767
Filing Date
January 12, 2006
Published for Opposition
September 19, 2006
Abandonment Date
January 11, 2010
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Jan 11, 2010
Classes
005

Rights Holder

Epigenesis Pharmaceuticals, LLC

16
Address
2009 Eastpark Boulevard
Cranbury, NJ 08512

Ownership History

Epigenesis Pharmaceuticals, LLC

Original Applicant
16
Cranbury, NJ

Epigenesis Pharmaceuticals, LLC

Owner at Publication
16
Cranbury, NJ

Legal Representation

Attorney
Albert P. Halluin

USPTO Deadlines

All Deadlines Cleared

All 2 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

29 events
Date Code Type Description
Jan 11, 2010 ABN6 S ABANDONMENT - NO USE STATEMENT FILED
Jan 11, 2010 MAB6 O ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Jun 30, 2009 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jun 30, 2009 EX5G S EXTENSION 5 GRANTED
Jun 8, 2009 EEXT I TEAS EXTENSION RECEIVED
Jun 8, 2009 EXT5 S EXTENSION 5 FILED
Dec 1, 2008 EEXT I TEAS EXTENSION RECEIVED
Dec 1, 2008 EXT4 S EXTENSION 4 FILED
Dec 1, 2008 EX4G S EXTENSION 4 GRANTED
Jun 4, 2008 EEXT I TEAS EXTENSION RECEIVED
Jun 4, 2008 EXT3 S EXTENSION 3 FILED
Jun 4, 2008 EX3G S EXTENSION 3 GRANTED
Dec 3, 2007 EEXT I TEAS EXTENSION RECEIVED
Dec 3, 2007 EXT2 S EXTENSION 2 FILED
Dec 3, 2007 EX2G S EXTENSION 2 GRANTED
Jun 5, 2007 EEXT I TEAS EXTENSION RECEIVED
Jun 5, 2007 EXT1 S EXTENSION 1 FILED
Jun 5, 2007 EX1G S EXTENSION 1 GRANTED
Dec 12, 2006 NOAM O NOA MAILED - SOU REQUIRED FROM APPLICANT
Sep 19, 2006 PUBO A PUBLISHED FOR OPPOSITION
Aug 30, 2006 NPUB O NOTICE OF PUBLICATION
Jul 27, 2006 PREV O LAW OFFICE PUBLICATION REVIEW COMPLETED
Jul 21, 2006 ALIE A ASSIGNED TO LIE
Jul 17, 2006 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 13, 2006 CNEA R EXAMINERS AMENDMENT -WRITTEN
Jul 13, 2006 GNEA F EXAMINERS AMENDMENT E-MAILED
Jul 13, 2006 XAEC I EXAMINER'S AMENDMENT ENTERED
Jun 29, 2006 DOCK D ASSIGNED TO EXAMINER
Jan 18, 2006 NWAP I NEW APPLICATION ENTERED IN TRAM

Detailed Classifications

Class 005
medical diagnostic and therapeutic preparations, all for administration via diverse routes of administration including through the respiratory airways, and, medical devices for administering the pharmaceuticals, sold filled, the preparations including nucleotides, proteins and organic molecules for medical use, including macromolecules such as anti-sense oligonucleotides and enzymes and small and inorganic molecules for treatment of human and non-human animal respiratory, central nervous system, neoplastic, endocrine, immune and cardiovascular ailments, including bronchoconstriction, difficult breathing, impeded and obstructed lung airways, allergy(ies) and/or inflammation, which in some cases are adenosine receptor associated symptoms; pharmaceutical preparations for testing, and preventing and therapeutically treating respiratory, airway and pulmonary diseases and conditions, such as asthma, pulmonary vasconconstriction, inflammation, allergies, impeded respiration, acute respiratory disease syndrome (ARDS), renal damage and failure, ischemia resulting from the administration of certain drugs, including adenosine and other drugs for, for example, treating supra ventricular tachycardia (SVT), adenosine stress tests, infantile respiratory distress syndrome (infantile RDS), pain, cystic fibrosis, allergic rhinitis, allergic bronchitis, pulmonary hypertension, pulmonary vasconcontriction, emphysema, chronic obstructive pulmonary disease (COPD), as well as cancers including leukemias, lymphomas, carcinomas, and the like, eg colon cancer, breast cancer, lung cancer, pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma, etc, as well as metastatic cancers, eg, cancers which metastasized to the lung(s), breast, liver and prostate
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
005

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"PHARMACEUTICALS"

USPTO Documents

Loading USPTO documents...